Enlivex Therapeutics Ltd (ENLV) - Total Liabilities

Latest as of September 2025: ILA3.46 Million ILA ≈ $9.27K USD

Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has total liabilities worth ILA3.46 Million ILA (≈ $9.27K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ENLV long-term investments to assets to see how much of total assets are deployed in long-term investments.

Enlivex Therapeutics Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how Enlivex Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Enlivex Therapeutics Ltd (ENLV) total assets.

Enlivex Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Enlivex Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Premier Miton Group plc LSE:PMI	UK	GBX109.89 Million
Diagonal Bio AB ST:DIABIO	Sweden	Skr2.13 Million
Greencastle Resources Ltd. V:VGN	Canada	CA$73.75K
Darmi Bersaudara Tbk PT JK:KAYU	Indonesia	Rp17.84 Billion
Maven Income And Growth Vct 5 Plc LSE:MIG5	UK	GBX1.16 Million
Black Spruce Exploration Inc. V:BARK	Canada	CA$2.83 Million
Mullen Automotive Inc. NASDAQ:MULN	USA	$196.28 Million
SecUR Credentials Limited NSE:SECURCRED	India	Rs-493.66 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Enlivex Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Enlivex Therapeutics Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	6.43	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.20	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.17	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Enlivex Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Enlivex Therapeutics Ltd (2012–2024)

The table below shows the annual total liabilities of Enlivex Therapeutics Ltd from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA4.10 Million ≈ $10.99K	-39.26%
2023-12-31	ILA6.75 Million ≈ $18.09K	-37.53%
2022-12-31	ILA10.80 Million ≈ $28.96K	+6.87%
2021-12-31	ILA10.11 Million ≈ $27.10K	+107.49%
2020-12-31	ILA4.87 Million ≈ $13.06K	-22.41%
2019-12-31	ILA6.28 Million ≈ $16.83K	+372.74%
2018-12-31	ILA1.33 Million ≈ $3.56K	+188.70%
2017-12-31	ILA460.00K ≈ $1.23K	-76.18%
2016-12-31	ILA1.93 Million ≈ $5.18K	-25.27%
2015-12-31	ILA2.58 Million ≈ $6.93K	+13.33%
2014-12-31	ILA2.28 Million ≈ $6.11K	+1640.46%
2013-12-31	ILA131.00K ≈ $351.21	+61.73%
2012-12-31	ILA81.00K ≈ $217.16	--

About Enlivex Therapeutics Ltd

TA:ENLV Israel Biotechnology

Market Cap

$700.05K

ILA261.12 Million ILA

Market Cap Rank

#30892 Global

#454 in Israel

Share Price

ILA1.10

Change (1 day)

-18.52%

52-Week Range

ILA0.57 - ILA484.00

All Time High

ILA14150.00